GlobeNewswire Inc | Sep 7, 2021 07:05AM EDT

September 07, 2021

LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

-- Citis 16th Annual BioPharma Virtual Conference, September 8 - 10, 2021Members of uniQures management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 9. -- Wells Fargo 2021 Virtual Healthcare Conference, September 9 - 10, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Friday, September 10.A fireside chat with Matt Kapusta will take place the same day from 12:00 to 12:30 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, September 15.A pre-recorded fireside chat with Matt Kapusta will be available on September 13th through H.C. Wainwright or can accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- SVB Leerink CybeRx Series: Neuromuscular, Rare Disease & Genetic Medicines Summit, September 22 - 23, 2021Members of uniQures management team including Ricardo Dolmetsch, Ph.D., president of Research & Development will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 23. -- 2021 Cantor Virtual Global Healthcare Conference, September 27 - 30, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Monday, September 27.Ricardo Dolmetsch will participate in a fireside chat the same day at 9:20 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimers, Parkinsons, and ALS. www.uniQure.com

uniQure Contacts:

FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com